Nature Communications (Sep 2022)
Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia
- Xujie Zhao,
- Ping Wang,
- Jonathan D. Diedrich,
- Brandon Smart,
- Noemi Reyes,
- Satoshi Yoshimura,
- Jingliao Zhang,
- Wentao Yang,
- Kelly Barnett,
- Beisi Xu,
- Zhenhua Li,
- Xin Huang,
- Jiyang Yu,
- Kristine Crews,
- Allen Eng Juh Yeoh,
- Marina Konopleva,
- Chia-Lin Wei,
- Ching-Hon Pui,
- Daniel Savic,
- Jun J. Yang
Affiliations
- Xujie Zhao
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Ping Wang
- The Jackson Laboratory for Genomic Medicine
- Jonathan D. Diedrich
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Brandon Smart
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Noemi Reyes
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Satoshi Yoshimura
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Jingliao Zhang
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Wentao Yang
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Kelly Barnett
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Beisi Xu
- Center for Applied Bioinformatics, St. Jude Children’s Research Hospital
- Zhenhua Li
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Xin Huang
- Department of Computational Biology, St. Jude Children’s Research Hospital
- Jiyang Yu
- Department of Computational Biology, St. Jude Children’s Research Hospital
- Kristine Crews
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Allen Eng Juh Yeoh
- Department of Pediatrics, National University of Singapore
- Marina Konopleva
- Departments of Leukemia, The University of Texas MD Anderson Cancer Center
- Chia-Lin Wei
- The Jackson Laboratory for Genomic Medicine
- Ching-Hon Pui
- Department of Oncology, St. Jude Children’s Research Hospital
- Daniel Savic
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- Jun J. Yang
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children’s Research Hospital
- DOI
- https://doi.org/10.1038/s41467-022-33143-w
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
Different molecular subtypes defined by specific gene rearrangements have been described for acute lymphoblastic leukaemia (ALL). Here, the authors show that ZNF384 fusion activates FLT3 expression conferring a therapeutic vulnerability for ZNF384- rearranged ALL subtype.
